Miragen Aims for IND in '15 as Part of Broad Corporate Strategy | GenomeWeb

NEW YORK (GenomeWeb) – As it continued work on three microRNA drug programs with partner Servier, Miragen Therapeutics is also advancing a pipeline of proprietary candidates and aims to move one into clinical testing as early as next year.

According to Miragen President and CEO William Marshall, this goal represents one part of a broad corporate strategy, dubbed 10-3-1, that envisions key milestones for the company by the end of 2017.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.